Expression, purification, crystallization and preliminary diffraction data characterization of *Escherichia coli* ribonuclease II (RNase II)

RNA degradation is important in the post-transcriptional control of gene expression. The processing, degradation and quality control of RNA is performed by many different classes of ribonucleases. Ribonuclease II (RNase II) is a 643-amino-acid enzyme that degrades single-stranded RNA from its 3'-end, releasing ribonucleoside 5'-monophosphates. RNase II was expressed both as the wild type and as a D209N mutant form. The latter was also produced as an SeMet derivative. The various protein forms were crystallized using the vapour-diffusion method. Wild-type RNase II was crystallized in two crystal forms, both of which belonged to space group *P*2₁. X-ray diffraction data were collected to 2.44 and 2.75 Å resolution, with unit-cell parameters *a* = 56.8, *b* = 125.7, *c* = 66.2 Å, *β* = 111.9° and *a* = 119.6, *b* = 57.2, *c* = 121.2 Å, *β* = 99.7°, respectively. The RNase II D209N mutant gave crystals that belonged to space group *P*6₅, with unit-cell parameters *a* = *b* = 86.3, *c* = 279.2 Å, and diffracted to 2.74 Å. Diffraction data from the mutant and its SeMet derivative enabled the determination of a partial Se-atom substructure by SIRAS.

1. Introduction

The levels of mRNA in a cell are a function of its synthesis and degradation. mRNA degradation is the result of the combined action of endonucleases and exonucleases (Regnier & Arraiano, 2000; Arraiano & Maquat, 2003). In *Escherichia coli*, RNase II and PNPase are the two main 3' to 5' exoribonucleases. RNase II is an Mg²⁺-dependent hydrolase that degrades single-stranded RNA, creating ribonucleoside 5'-monophosphate products. RNase II is the prototype of the RNB superfamily of exoribonucleases (Mian, 1997) acting as a non-specific ribonuclease that degrades single-stranded RNA processively. When the length of the single-stranded RNA substrate reaches ~10 nucleotides it becomes more distributive and finally leaves an undigested core of 3–5 nucleotides. A single mutation in *E. coli* ribonuclease II has been shown to inactivate the enzyme without affecting RNA binding. This mutation, D209N, is at a highly conserved residue that has been proposed to be involved in metal-ion binding (Amblar & Arraiano, 2005). Although the mutant is totally inactive, it still retains the ability to bind the substrate (Amblar & Arraiano, 2005). Here, we describe the expression and purification of RNase II D209N and its SeMet derivative and the crystallization, heavy-atom derivatization attempts and preliminary diffraction data characterization of both wild-type (wt) and D209N mutant forms of RNase II.

2. Materials and methods

2.1. Protein expression and purification

RNase II was overexpressed in *E. coli* BL21 (DE3) and purified as previously described (Amblar & Arraiano, 2005): the protein was concentrated to 8.5 mg ml⁻¹ using an Amicon Ultra centrifugal filter (molecular-weight cutoff 30 kDa; Millipore) in the presence of 3% glycerol, 1 mM MgCl₂, 100 mM KCl and 100 mM Tris–HCl pH 8.0.
The methods for expression and purification of the RNase II D209N mutant followed similar procedures, with the modifications outlined below.

For expression of RNase II D209N, the plasmid pMAA (Amblar & Arraiano, 2005) was transformed into E. coli strain BL21 (DE3) (Novagen). Cultures were grown in LB media supplemented with 150 μg ml⁻¹ ampicillin at 310 K until an OD₆₀₀ of 0.4 was reached. Expression was induced by the addition of 1 mM IPTG and the cultures were grown for a further 2 h at 310 K.

Selenomethionine-derivatized D209N protein was produced by transforming the pMAA plasmid into the auxotrophic strain E. coli B834 (DE3). Cells were cultured in SelenoMet Minimal Media (Molecular Dimensions Ltd) according to the manufacturer’s instructions with the introduction of the following modifications. Briefly, a single colony was initially grown in LB medium (for about 8 h). 10 ml SelenoMet Minimal Medium containing l-methionine and Nutrient Mix (Molecular Dimensions Ltd) and supplemented with 150 μg ml⁻¹ ampicillin was then inoculated with the culture in a 1:20 ratio. This new culture was grown overnight and centrifuged at 5000 g and the pellet was washed with sterile minimal medium in order to eliminate any residual methionine. The pellet was then used to inoculate a 500 ml flask of SelenoMet minimal medium containing l-selenomethionine as directed by the manufacturer. The culture was grown to the point of induction, OD₆₀₀ = 0.65, which was followed by addition of IPTG to 0.5 mM and growth for a further 1–2 h at 310 K.

Both native and selenomethionine-derivatized D209N proteins were purified as follows. The cells were harvested by centrifugation at 10 000 g for 30 min and the bacterial pellets were resuspended in 500 mM NaCl and 50 mM Tris–HCl pH 8.0 (buffer A) plus 1 mM PMSF and 20 mM imidazole and the cells were lysed using a French press at 131 MPa. The cell lysate was incubated on ice for 1 h with 100 U benzonase (Novagen), the sample was clarified by centrifugation at 20 000 g for 30 min and the supernatant was loaded onto a HisTrap-Chelating HP column (Amersham Biosciences). After washing with ten column volumes of buffer A plus 20 mM imidazole, the protein was gradient eluted with buffer A plus 500 mM imidazole.

Fractions containing pure protein were selectively pooled and DTT was added to 1 mM; peaks I, II and III were pooled separately (Fig. 1). The purified protein was concentrated to 10 mg ml⁻¹ in 20 mM Tris–HCl pH 8, 150 mM NaCl, 10% glycerol and 1 mM DTT.

For expression of RNase II D209N, the plasmid pMAA was transformed into E. coli strain BL21 (DE3) (Novagen). Cultures were grown in LB media supplemented with 150 μg ml⁻¹ ampicillin at 310 K until an OD₆₀₀ of 0.4 was reached. Expression was induced by the addition of 1 mM IPTG and the cultures were grown for a further 2 h at 310 K.

Selenomethionine-derivatized D209N protein was produced by transforming the pMAA plasmid into the auxotrophic strain E. coli B834 (DE3). Cells were cultured in SelenoMet Minimal Media (Molecular Dimensions Ltd) according to the manufacturer’s instructions with the introduction of the following modifications. Briefly, a single colony was initially grown in LB medium (for about 8 h). 10 ml SelenoMet Minimal Medium containing l-methionine and Nutrient Mix (Molecular Dimensions Ltd) and supplemented with 150 μg ml⁻¹ ampicillin was then inoculated with the culture in a 1:20 ratio. This new culture was grown overnight and centrifuged at 5000 g and the pellet was washed with sterile minimal medium in order to eliminate any residual methionine. The pellet was then used to inoculate a 500 ml flask of SelenoMet minimal medium containing l-selenomethionine as directed by the manufacturer. The culture was grown to the point of induction, OD₆₀₀ = 0.65, which was followed by addition of IPTG to 0.5 mM and growth for a further 1–2 h at 310 K.

Both native and selenomethionine-derivatized D209N proteins were purified as follows. The cells were harvested by centrifugation at 10 000 g for 30 min and the bacterial pellets were resuspended in 500 mM NaCl and 50 mM Tris–HCl pH 8.0 (buffer A) plus 1 mM PMSF and 20 mM imidazole and the cells were lysed using a French press at 131 MPa. The cell lysate was incubated on ice for 1 h with 100 U benzonase (Novagen), the sample was clarified by centrifugation at 20 000 g for 30 min and the supernatant was loaded onto a HisTrap-Chelating HP column (Amersham Biosciences). After washing with ten column volumes of buffer A plus 20 mM imidazole, the protein was gradient eluted with buffer A plus 500 mM imidazole.

Fractions containing pure protein were selectively pooled and DTT was added to 1 mM; peaks I, II and III were pooled separately (Fig. 1). The purified protein was concentrated to 10 mg ml⁻¹ in 20 mM Tris–HCl pH 8, 150 mM NaCl, 10% glycerol and 1 mM DTT.

In anticipation that the 6×His tag at the N-terminus might interfere with crystal packing, it was removed in some of the batches. Cleavage took place using biotinylated thrombin in a cleavage capture kit (Novagen). Digestion was performed by overnight incubation at 293 K with 2.5 U thrombin per milligram of pure protein. Thrombin was subsequently removed using immobilized streptavidin beads, as described in the manufacturer’s instructions.
2.2. Crystallization

2.2.1. Wild-type RNase II. Crystallization trials were performed by the sitting-drop vapour-diffusion method using Hampton Research Crystal Screen 1 and Natrix 1 and Molecular Dimensions Crystal Strategy Screens 1 and 2. Crystals of purified RNase II were grown, with or without the His tag, in 24-well Linbro plates, mixing 1.5 μl protein solution and 1.5 μl reservoir solution and equilibrating the drops against 500 μl reservoir solution. Optimized crystals from initial batches of the wild-type (wt) enzyme, hereby called P21, form A crystals, were obtained as thin plates with dimensions of up to 0.4 × 0.15 × 0.08 mm in 22% PEG 4K, 0.6 M calcium acetate and 0.1 M Tris–HCl pH 8.5 at 293 K (Fig. 2a). Subsequent batches were concentrated to 12 mg ml\(^{-1}\) in the presence of 2% glycerol, 100 mM NaCl, 20 mM Tris–HCl pH 7. These produced a different crystal form, referred to here as P21, form B, with dimensions of 0.1 × 0.05 × 0.02 mm and with optimized crystallization conditions of 25% PEG 8K and 0.2 M HEPES pH 7.5 at 277 K. Production of heavy-atom derivatives was attempted by soaking crystals for 1–2 d in crystallization solution complemented with metal salts and back-soaking the crystals for 3 min in crystallization solution containing 25%\(\text{Na}_{2}\text{MoO}_{4}\) and 0.2% glycerol. Alternatively, derivatization with heavy halides was also attempted by soaking the crystals for 1–2 min in crystallization solution complemented with halides and 25%\(\text{Na}_{2}\text{MoO}_{4}\) and 0.2% glycerol. Crystals soaked with salts of Pt, Au, I and Br were flash-cooled in liquid nitrogen and their diffraction examined and eventually collected if suitable diffraction resolution was achieved. Diffraction data sets were obtained from putative derivatives of Pt, Au and I, in addition to native data.

2.2.2. RNase II D209N. Initial crystallization conditions were screened with a nanodrop crystallization robot (Cartesian Technologies) and the standard conditions of the EMBL Partnership for Structural Biology High-Throughput Crystallization Robot (EMBL, Grenoble) using the sitting-drop vapour-diffusion method. Each drop was prepared by mixing 100 nl protein solution with an equal amount of crystallization solution and equilibrated by vapour diffusion against 100 μl crystallization solution in the reservoir at 293 K. Crystals were initially obtained in both 2.4 M ammonium sulfate pH 6–9 and 1.9–2.4 M sodium malonate pH 6–7 screens (Hampton Research). Such crystals grew to dimensions of 0.1 × 0.06 × 0.06 mm and diffracted to 3.5 Å resolution (data not shown).

After selective fractionation during the purification step (Fig. 1) and without removal of the N-terminal His tag, single crystals were obtained at 293 K both in 2.3–2.5 M ammonium sulfate, 0.1 M MES pH 6–9 or in 2.2–2.4 M sodium malonate pH 6–9 using sitting-drop vapour diffusion. However, crystallization only took place for pooled fractions I and II; even with further purification pooled fraction III proved recalcitrant to crystallization. Crystals for X-ray analysis were grown using the sitting-drop vapour-diffusion method by mixing 1.5 μl protein solution with 1.5 μl reservoir solution (2.4 M sodium malonate pH 6.0) and equilibrating against 500 μl reservoir solution at 293 K (Fig. 2b). They were harvested in 2.5 M sodium malonate pH 6.0, which proved to be an adequate cryoprotectant. This procedure, in particular the chromatographic step, led to reproducible crystals, prompting a screen of heavy-atom derivatives by soaking crystals in metal-salt solutions (5 mM) for 2 d in the harvesting solution. Crystals were then back-soaked for 2 min in 2.5 M sodium malonate pH 6.0 and flash-cooled in liquid nitrogen. Diffraction data were collected from the native mutant, its SeMet derivative and other putative heavy atom derivatives.

2.3. Crystallographic characterization and diffraction data collection, processing and analysis

X-ray data were collected at cryotemperatures using monochromatic synchrotron radiation (see Table 1 for further details). Data were indexed, processed and scaled with the HKL package (Otwinowski & Minor, 1997). The graphical user interface HKL2MAP (Pape & Schneider, 2004) was used with SHELXC (G. M. Sheldrick,
personal communication) to scale and analyse isomorphous and/or anomalous data, using SHELXD (Schneider & Sheldrick, 2002) to locate heavy-atom substructures and SHELXE (Sheldrick, 2002) to validate the obtained solutions and produce experimental maps, which were examined with Xfit (McRee, 1999). Using the anomalous differences between RNase II D209N and its SeMet derivative, an Se substructure and the corresponding experimental maps were obtained by SIRAS (Fig. 3). Although the electron-density maps still do not allow a clear assignment of the polypeptide chain, one can recognize potential protein and solvent regions.

3. Discussion and conclusions

For the inactive mutant RNase II D209N, purification by selective fractionation of the protein in the gradient elution provided a source of homogeneous protein that enabled improved reproducibility of crystals relative to the wild-type forms, which had been purified using a previous protocol (Amblar & Arraiano, 2005). The heterogeneity shown in the elution peak suggests the possibility of RNA binding during the purification step of the D209N mutant. In terms of crystal reproducibility and the final quality of the different crystal forms of RNase II, we could not establish any correlation with protein batches that included or excluded the N-terminal 6×His tag.

Two monoclinic crystal forms of wt RNase II and a hexagonal form of its D209N mutant were obtained. Attempts to solve the phase problem using any of the monoclinic native data sets in conjunction with putative heavy-atom derivatives have remained unsuccessful to date. The RNase II D209N mutant produced crystals belonging to space group P6₁ or P6₅. The diffraction data of the mutant and its SeMet derivative enabled the determination of an Se substructure and a set of experimental phases by SIRAS (Fig. 3). As the SeMet-derivative data were collected for phasing purposes, the resolution was cut off at 3.5 Å, near its anomalous signal reliability limit (Fig. 3a).

The number of sites in the heavy-atom substructure shows that the crystal contains one protein molecule in the asymmetric unit (Fig. 3b), corresponding to a calculated solvent content of 65%. The hexagonal space-group ambiguity was solved by SHELXE, as both the ‘map contrast’ (Fig. 3c) and ‘map connectivity’ statistics calculated for space group P6₁ clearly converge to higher values than those calculated for the alternative P6₅ space-group possibility. Additionally, the ‘map connectivity’ converged to 0.915, indicating that the phase problem may have been solved as it is above the 0.9 threshold (Sheldrick, 2002). Improvements of the solution of the phase problem in order to obtain the RNase II structure are in progress.

We would like to thank the staff of the High-Throughput Crystallization Laboratory of the EMBL Grenoble Outstation for crystallization screens and the ESRF maintenance and operation of the beamlines the staff at beamlines ID-13 and ID-14 for technical support. This work was supported by grants from Fundação para a Ciência e Tecnologia.

References